AXSM · Company research
Axsome Therapeutics, Inc (AXSM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight | The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| 2 Under-the-Radar Stocks to Buy and Hold | The article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.667 | 1 |
| 2 Under-the-Radar Stocks to Buy and Hold | The article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.667 | 1 |
| Axsome Therapeutics (NASDAQ:AXSM) Stock Price Up 4.4% - Here's Why - MarketBeat | Axsome Therapeutics (NASDAQ:AXSM) Stock Price Up 4.4% - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| Why Axsome Therapeutics shares are falling today - Quiver Quantitative | Why Axsome Therapeutics shares are falling today Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 13, 2026 | neutral | 0 | 0.6 |
| Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo! Finance Canada | Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance | Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? | Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? | Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? | Axsome Therapeutics' Auvelity drug is expanding beyond major depressive disorder into Alzheimer's agitation treatment, with Q2 sales reaching $180.3 million (up 51% YoY) and new patient starts among seniors jumping 126% post-launch. The company projects Auvelity could eventually generate $8 billion in annual peak sales, with additional commercial products and pipeline candidates potentially transforming Axsome into a major neuroscience pharmaceutical company by 2030. | View source ↗ | The Motley Fool | Oct 12, 2026 | bullish | 1 | 1 |
| 4 CNS Drug Stocks Worth Watching This World Mental Health Day | Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| 4 CNS Drug Stocks Worth Watching This World Mental Health Day | Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| 10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13% - Trefis | 10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13% Trefis | View source ↗ | Trefis | Oct 9, 2026 | neutral | 0 | 0.6 |
| AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - Stocktwits | AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days - Trefis | Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days Trefis | View source ↗ | Trefis | Oct 8, 2026 | neutral | 0 | 0.6 |
| Before markets open Nov. 2, Axsome will report results and host an 8 a.m. call. - Stock Titan | Before markets open Nov. 2, Axsome will report results and host an 8 a.m. call. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance | Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) Yahoo Finance | View source ↗ | Yahoo Finance | Oct 5, 2026 | neutral | 0 | 0.6 |
| Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions - Simply Wall Street | Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat | Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade MarketBeat | View source ↗ | MarketBeat | Sep 29, 2026 | neutral | 0 | 0.6 |
| Three in four caregivers wish they had recognized Alzheimer’s agitation sooner - Stock Titan | Three in four caregivers wish they had recognized Alzheimer’s agitation sooner Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues - Yahoo Finance | Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues Yahoo Finance | View source ↗ | Yahoo Finance | Sep 19, 2026 | neutral | 0 | 0.6 |
| Axsome Therapeutics (AXSM) Stock Faces Revenue Momentum And Lingering Losses - Simply Wall Street | Axsome Therapeutics (AXSM) Stock Faces Revenue Momentum And Lingering Losses Simply Wall Street | View source ↗ | Simply Wall Street | Aug 12, 2026 | neutral | 0 | 0.6 |
| Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug - Yahoo Finance | Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug Yahoo Finance | View source ↗ | Yahoo Finance | Jul 24, 2026 | neutral | 0 | 0.6 |
| Why Axsome Therapeutics (AXSM) Stock Is Down Today - Quiver Quantitative | Why Axsome Therapeutics (AXSM) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 10, 2026 | neutral | 0 | 0.6 |
| AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits | AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week Stocktwits | View source ↗ | Stocktwits | Apr 29, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.